WO2023047151 - CANCER BIOMARKERS FOR SUSCEPTIBILITY TO TREATMENT BY ALMITRINE
National phase entry:
Publication Number
WO/2023/047151
Publication Date
30.03.2023
International Application No.
PCT/IB2021/058639
International Filing Date
22.09.2021
Title **
[English]
CANCER BIOMARKERS FOR SUSCEPTIBILITY TO TREATMENT BY ALMITRINE
[French]
BIOMARQUEURS DU CANCER POUR LA SUSCEPTIBILITÉ AU TRAITEMENT PAR ALMITRINE
Applicants **
FORREST, Michael, David
Inventors
FORREST, Michael, David
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2519 | |
| EPO | Filing, Examination, Granting | 10095 | |
| Japan | Filing, Examination, Granting | 2488 | |
| South Korea | Filing, Examination, Granting | 2536 | |
| USA | Filing, Examination, Granting | 7140 |
Total:
24,778
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Biomarkers of cancer susceptibility/resistance to almitrine treatment are disclosed.[French]
L'invention concerne des biomarqueurs de la sensibilité/résistance du cancer à un traitement par almitrine.